Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05791201 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

A Phase 1 study of Type 1 Diabetes, sponsored by Vertex Pharmaceuticals Incorporated.

Active
Registry status
Phase 1
Development phase
7
Enrollment target
16
Study locations

NCT05791201: Active Phase 1 study of Type 1 Diabetes, sponsored by Vertex Pharmaceuticals Incorporated.

NCT05791201 is a Phase 1 study of Type 1 Diabetes that is active but no longer recruiting, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 7 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05791201, a Phase 1 study of Type 1 Diabetes, is active but no longer recruiting, sponsored by Vertex Pharmaceuticals Incorporated.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
7 participants
Enrollment target
16
Study locations

Study Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Conditions Studied

Type 1 Diabetes

Interventions

  • DRUG VX-264

Study Locations (16)

Other

  • University of Alberta, Edmonton - Edmonton
  • Montreal Clinical Research Institute - Montreal
  • Toronto General Hospital (TGH) - Toronto
  • Vancouver General Hospital - Vancouver
  • Dresden Center for Islet Transplantation - Dresden
  • IRCCS Ospedale San Raffaele - Milan
  • Leiden University - Leiden
  • Hopiteaux Universitaires de Geneve - Geneva
  • Churchill Hospital - Headington
  • Royal Victoria Infirmary - Newcastle upon Tyne

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center Montefiore - Pittsburgh

Florida

  • UHealth Diabetes Research Institute - Miami

Illinois

  • University of Chicago - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2023-05-16
Est. Completion 2026-05-29
Phase Phase 1
Vertex Pharmaceuticals Incorporated

191 total trials

What the registry record for NCT05791201 still lists

NCT05791201 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which VX-264 is the first listed.

NCT05791201 lists 16 locations in 6 states (Other, Pennsylvania, Florida).

Frequently Asked Questions

What is clinical trial NCT05791201 about?

NCT05791201 is a clinical study titled "A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes". The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

What is the current status of trial NCT05791201?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-05-16. Estimated completion is 2026-05-29.

What conditions does trial NCT05791201 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT05791201?

The interventions under investigation include: VX-264 (DRUG).

Who is sponsoring clinical trial NCT05791201?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05791201 being conducted?

This trial has 16 study locations across Florida, Illinois, Massachusetts, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05791201's enrollment target sits among peer trials

7 194th of 198 higher than 4 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05791201, the US trial registry maintained by the National Library of Medicine. NCT05791201 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.